- $992.16m
- $495.09m
- $32.33m
Brief: Verve Therapeutics Announces Verve-101 Awarded Innovation Passport By The Uk Mhra For The Treatment Of Heterozygous Familial Hypercholesterolemia
Lifting FDA hold on heart drug trial top 2023 priority for Verve - RBC
U.S. STOCKS ON THE MOVE-Pot stocks, Nymox, Zynerba
U.S. STOCKS ON THE MOVE-TFF Pharma, BioRestorative,
Verve Therapeutics drops as FDA puts heart drug study on hold
U.S. STOCKS ON THE MOVE-Boeing, U.S. energy, Delek US
U.S. STOCKS ON THE MOVE-Kosmos Energy, Scisparc, Walgreens
U.S. STOCKS ON THE MOVE-IAA, Fluor, Oyster Point
Verve Therapeutics slumps as U.S. FDA places heart disease trial on hold
Brief: Verve Therapeutics Provides Regulatory Update On Verve-101 And Reports Q3 Financial Results
Brief: Verve Therapeutics Reports Clearance Of Clinical Trial Authorisation Application By UK Health Regulator For Verve-101
Brief: Verve Therapeutics Highlights Preclinical Data Supporting Nomination Of Verve-201 ANGPTl3 Product Candidate
Brief: Verve Therapeutics reports Q2 results
Brief: Verve Therapeutics Announces Closing Of Upsized Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Rivian, One Medical, Evofem Biosciences
U.S. STOCKS ON THE MOVE-Philip Morris, AT&T, Olema Pharmaceuticals
Verve Therapeutics slides on upsized share offering
Brief: Verve Delivers Notice To Jefferies About Suspension Of ATM Prospectus Related To Stock Sale
Brief: Verve Therapeutics Announces Pricing Of Upsized Public Offering Of Common Stock